Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Question about Amgen's lead in TPO race

Robertson, Stephens analyst Edward Hurwitz on Friday said that, based on information he gleaned from Japanese publications, Amgen Inc.'s lead in the thrombopoietin race may be tenuous.

AMGN in April became the first company in the TPO race - the others being Genentech Inc., Novo Nordisk subsidiary ZymoGenetics, and AMGN's partner Kirin - to enter the protein that stimulates platelet production into clinical trials.

However, Hurwitz said that AMGN's version of the drug

Read the full 715 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE